AFP and metastatic neoplasm: Based on these specific prognostic factors, the CHIC group recently developed a new HB risk-stratified staging system, named CHIC–HB Stratification (CHIC–HS), according to five group classifications which showed a 5-year EFS of 86% for PRETEXT I/II, 82% for PRETEXT III, 60% for PRETEXT IV, 42% for metastatic disease, and 35% for AFP concentration ≤ 100 ng/mL at diagnosis [2].